NASDAQ:KALV - KalVista Pharmaceuticals Stock Price, Price Target & More

$9.16 -0.06 (-0.65 %)
(As of 04/20/2018 04:00 PM ET)
Previous Close$9.16
Today's Range$9.16 - $9.3904
52-Week Range$5.48 - $15.80
Volume11,296 shs
Average Volume36,764 shs
Market Capitalization$102.89 million
P/E RatioN/A
Dividend YieldN/A
Beta2.5

About KalVista Pharmaceuticals (NASDAQ:KALV)

KalVista Pharmaceuticals logoKalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products under development include KVD818, an orally delivered molecule that is in Phase I clinical trial for the treatment of HAE; KVD001, an intravitreally administered plasma kallikrein inhibitor that has completed a Phase I clinical trials for the treatment of DME; and KVD900, a potent inhibitor of plasma kallikrein that is in preclinical safety studies for use against human proteases related to plasma kallikrein. The company is headquartered in Cambridge, Massachusetts.

Receive KALV News and Ratings via Email

Sign-up to receive the latest news and ratings for KALV and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:KALV
CUSIPN/A
Phone857-999-0075

Debt

Debt-to-Equity RatioN/A
Current Ratio2.73%
Quick Ratio2.73%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.50 million
Price / Sales65.95
Cash FlowN/A
Price / CashN/A
Book Value$3.22 per share
Price / Book2.84

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-18,600,000.00
Net Margins-527.53%
Return on Equity-65.77%
Return on Assets-46.48%

Miscellaneous

Employees28
Outstanding Shares10,800,000

How to Become a New Pot Stock Millionaire

KalVista Pharmaceuticals (NASDAQ:KALV) Frequently Asked Questions

What is KalVista Pharmaceuticals' stock symbol?

KalVista Pharmaceuticals trades on the NASDAQ under the ticker symbol "KALV."

How were KalVista Pharmaceuticals' earnings last quarter?

KalVista Pharmaceuticals (NASDAQ:KALV) announced its earnings results on Friday, March, 16th. The specialty pharmaceutical company reported ($0.49) earnings per share (EPS) for the quarter. The specialty pharmaceutical company earned $2.33 million during the quarter. KalVista Pharmaceuticals had a negative net margin of 527.53% and a negative return on equity of 65.77%. View KalVista Pharmaceuticals' Earnings History.

What price target have analysts set for KALV?

1 brokerages have issued 12 month price objectives for KalVista Pharmaceuticals' stock. Their predictions range from $27.00 to $27.00. On average, they expect KalVista Pharmaceuticals' share price to reach $27.00 in the next year. View Analyst Ratings for KalVista Pharmaceuticals.

Who are some of KalVista Pharmaceuticals' key competitors?

Who are KalVista Pharmaceuticals' key executives?

KalVista Pharmaceuticals' management team includes the folowing people:
  • Mr. Thomas Andrew Crockett M.B.A., CEO & Director (Age 43)
  • Mr. Benjamin L. Palleiko, Chief Financial Officer (Age 52)
  • Mr. Andreas Maetzel M.D., M.Sc., Ph.D., Sr. VP of Medical (Age 55)
  • Mr. John B. McKune, VP of Fin. (Age 42)
  • Dr. Edward P. Feener Ph.D., Chief Scientific Officer (Age 58)

Has KalVista Pharmaceuticals been receiving favorable news coverage?

Press coverage about KALV stock has been trending somewhat positive this week, according to Accern. Accern scores the sentiment of press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. KalVista Pharmaceuticals earned a daily sentiment score of 0.09 on Accern's scale. They also gave media coverage about the specialty pharmaceutical company an impact score of 44.46 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near future.

How do I buy shares of KalVista Pharmaceuticals?

Shares of KALV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is KalVista Pharmaceuticals' stock price today?

One share of KALV stock can currently be purchased for approximately $9.16.

How big of a company is KalVista Pharmaceuticals?

KalVista Pharmaceuticals has a market capitalization of $102.89 million and generates $1.50 million in revenue each year. KalVista Pharmaceuticals employs 28 workers across the globe.

How can I contact KalVista Pharmaceuticals?

KalVista Pharmaceuticals' mailing address is 55 Cambridge Parkway Suite 901E, CAMBRIDGE MA, 02142. The specialty pharmaceutical company can be reached via phone at 857-999-0075 or via email at [email protected]


MarketBeat Community Rating for KalVista Pharmaceuticals (KALV)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  118 (Vote Outperform)
Underperform Votes:  81 (Vote Underperform)
Total Votes:  199
MarketBeat's community ratings are surveys of what our community members think about KalVista Pharmaceuticals and other stocks. Vote "Outperform" if you believe KALV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KALV will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

KalVista Pharmaceuticals (NASDAQ:KALV) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
1 Wall Street analysts have issued ratings and price targets for KalVista Pharmaceuticals in the last 12 months. Their average twelve-month price target is $27.00, suggesting that the stock has a possible upside of 194.76%. The high price target for KALV is $27.00 and the low price target for KALV is $27.00. There are currently 1 buy rating for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $27.00$27.00$27.00$27.00
Price Target Upside: 194.76% upside177.21% upside177.21% upside177.21% upside

KalVista Pharmaceuticals (NASDAQ:KALV) Consensus Price Target History

Price Target History for KalVista Pharmaceuticals (NASDAQ:KALV)

KalVista Pharmaceuticals (NASDAQ:KALV) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/16/2017BTIG ResearchBoost Price TargetBuy$18.00 -> $27.00N/AView Rating Details
(Data available from 4/21/2016 forward)

Earnings

KalVista Pharmaceuticals (NASDAQ:KALV) Earnings History and Estimates Chart

Earnings by Quarter for KalVista Pharmaceuticals (NASDAQ:KALV)

KalVista Pharmaceuticals (NASDAQ KALV) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/16/2018Q3 2018($0.49)$2.33 millionViewN/AView Earnings Details
12/14/2017Q2 2018($0.45)($0.50)$1.13 millionViewN/AView Earnings Details
9/14/2017Q1 2018($0.59)($0.51)$0.10 millionViewN/AView Earnings Details
7/27/2017Q4 2017($0.43)$0.11 millionViewN/AView Earnings Details
11/8/2016Q3 2016($0.21)($0.09)$0.01 millionViewN/AView Earnings Details
8/12/2016Q1 2017($3.50)($3.92)$0.01 millionViewN/AView Earnings Details
5/12/2016Q4 2016($2.66)($3.50)$0.01 millionViewN/AView Earnings Details
3/30/2016Q3 2016($2.66)$0.01 millionViewN/AView Earnings Details
11/11/2015Q315($0.26)($0.19)$0.01 million$0.01 millionViewListenView Earnings Details
8/11/2015Q215($0.21)($0.37)$0.01 million$0.01 millionViewListenView Earnings Details
5/19/2015Q4 2015($2.38)($103.36)$0.01 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

KalVista Pharmaceuticals (NASDAQ:KALV) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

KalVista Pharmaceuticals (NASDAQ KALV) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 49.10%
Institutional Ownership Percentage: 60.09%
Insider Trading History for KalVista Pharmaceuticals (NASDAQ:KALV)
Insider Trading History for KalVista Pharmaceuticals (NASDAQ:KALV)

KalVista Pharmaceuticals (NASDAQ KALV) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/12/2017Holdings A/S NovoMajor ShareholderSell2,725,283$9.64$26,271,728.12View SEC Filing  
10/12/2017Rajeev M ShahDirectorBuy850,000$8.50$7,225,000.00View SEC Filing  
9/15/2017Holdings A/S NovoMajor ShareholderSell176,647$7.21$1,273,624.872,876,027View SEC Filing  
9/14/2017Holdings A/S NovoMajor ShareholderSell10,000$8.05$80,500.002,876,027View SEC Filing  
9/13/2017Holdings A/S NovoMajor ShareholderSell25,900$8.02$207,718.002,876,027View SEC Filing  
12/30/2015David RenziCEOSell10,000$3.70$37,000.00View SEC Filing  
4/14/2015Acmp Iv LlcMajor ShareholderBuy877,500$5.00$4,387,500.00View SEC Filing  
4/14/2015Albert ChaDirectorBuy1,012,500$5.00$5,062,500.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

KalVista Pharmaceuticals (NASDAQ KALV) News Headlines

Source:
DateHeadline
KalVista Pharmaceuticals to Present Data at The Association for Research in Vision and Ophthalmology (ARVO) 2018 ...KalVista Pharmaceuticals to Present Data at The Association for Research in Vision and Ophthalmology (ARVO) 2018 ...
www.businesswire.com - April 20 at 10:03 AM
Management ReportManagement Report
finance.yahoo.com - April 3 at 10:16 AM
KalVista Pharmaceuticals Reports Fiscal Third Quarter Results ... - Business Wire (press release)KalVista Pharmaceuticals Reports Fiscal Third Quarter Results ... - Business Wire (press release)
www.businesswire.com - March 16 at 4:13 PM
Critical Review: ChemoCentryx (CCXI) versus Kalvista Pharmaceuticals (KALV)Critical Review: ChemoCentryx (CCXI) versus Kalvista Pharmaceuticals (KALV)
www.americanbankingnews.com - March 15 at 5:18 PM
Kalvista Pharmaceuticals (KALV) & Sonoma Pharmaceuticals (SNOA) Head-To-Head AnalysisKalvista Pharmaceuticals (KALV) & Sonoma Pharmaceuticals (SNOA) Head-To-Head Analysis
www.americanbankingnews.com - March 13 at 10:22 AM
KalVista Pharmaceuticals to Present at 30th Annual ROTH ConferenceKalVista Pharmaceuticals to Present at 30th Annual ROTH Conference
finance.yahoo.com - March 5 at 10:59 AM
Head-To-Head Contrast: Kalvista Pharmaceuticals (KALV) vs. Catalyst Biosciences (CBIO)Head-To-Head Contrast: Kalvista Pharmaceuticals (KALV) vs. Catalyst Biosciences (CBIO)
www.americanbankingnews.com - March 4 at 7:08 PM
KalVista Pharmaceuticals (KALV) Stock Rating Upgraded by ValuEngineKalVista Pharmaceuticals (KALV) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - February 5 at 12:58 AM
Reviewing Kadmon (KDMN) & KalVista Pharmaceuticals (KALV)Reviewing Kadmon (KDMN) & KalVista Pharmaceuticals (KALV)
www.americanbankingnews.com - January 25 at 9:48 AM
Merck Has Strong Conviction In KalVistas Phase 2 Clinical Trial Of KVD001 In DME - Seeking AlphaMerck Has Strong Conviction In KalVista's Phase 2 Clinical Trial Of KVD001 In DME - Seeking Alpha
seekingalpha.com - January 24 at 3:23 PM
Contrasting KalVista Pharmaceuticals (KALV) and Argos Therapeutics (ARGS)Contrasting KalVista Pharmaceuticals (KALV) and Argos Therapeutics (ARGS)
www.americanbankingnews.com - January 24 at 11:20 AM
BRIEF-Kalvista Pharmaceuticals Commences Two Clinical TrialsBRIEF-Kalvista Pharmaceuticals Commences Two Clinical Trials
www.reuters.com - January 5 at 10:55 AM
Contrasting KalVista Pharmaceuticals (KALV) and The CompetitionContrasting KalVista Pharmaceuticals (KALV) and The Competition
www.americanbankingnews.com - January 3 at 7:06 PM
KalVista Pharmaceuticals (KALV) Rating Increased to Sell at ValuEngineKalVista Pharmaceuticals (KALV) Rating Increased to Sell at ValuEngine
www.americanbankingnews.com - January 1 at 7:28 PM
ETFs with exposure to KalVista Pharmaceuticals, Inc. : January 1, 2018ETFs with exposure to KalVista Pharmaceuticals, Inc. : January 1, 2018
finance.yahoo.com - January 1 at 4:12 PM
Analyzing KalVista Pharmaceuticals (KALV) & Its RivalsAnalyzing KalVista Pharmaceuticals (KALV) & Its Rivals
www.americanbankingnews.com - December 31 at 5:30 AM
Reviewing KalVista Pharmaceuticals (KALV) and The CompetitionReviewing KalVista Pharmaceuticals (KALV) and The Competition
www.americanbankingnews.com - December 28 at 12:16 AM
ETFs with exposure to KalVista Pharmaceuticals, Inc. : December 19, 2017ETFs with exposure to KalVista Pharmaceuticals, Inc. : December 19, 2017
finance.yahoo.com - December 19 at 4:14 PM
KalVista Pharmaceuticals, Inc. :KALV-US: Earnings Analysis: Q2, 2018 By the Numbers : December 18, 2017KalVista Pharmaceuticals, Inc. :KALV-US: Earnings Analysis: Q2, 2018 By the Numbers : December 18, 2017
finance.yahoo.com - December 18 at 4:12 PM
KalVista Pharmaceuticals Reports Fiscal Second Quarter Results - Business Wire (press release)KalVista Pharmaceuticals Reports Fiscal Second Quarter Results - Business Wire (press release)
www.businesswire.com - December 16 at 10:42 AM
KalVista Pharmaceuticals (KALV) Releases  Earnings Results, Misses Expectations By $0.05 EPSKalVista Pharmaceuticals (KALV) Releases Earnings Results, Misses Expectations By $0.05 EPS
www.americanbankingnews.com - December 15 at 4:08 PM
KalVista Pharmaceuticals (KALV) & Its Peers Financial SurveyKalVista Pharmaceuticals (KALV) & Its Peers Financial Survey
www.americanbankingnews.com - December 11 at 11:22 PM
Head to Head Survey: KalVista Pharmaceuticals (KALV) vs. Its PeersHead to Head Survey: KalVista Pharmaceuticals (KALV) vs. Its Peers
www.americanbankingnews.com - December 8 at 7:46 PM
KalVista Pharmaceuticals to Present at Stifel Healthcare Conference - Business Wire (press release)KalVista Pharmaceuticals to Present at Stifel Healthcare Conference - Business Wire (press release)
www.businesswire.com - November 8 at 11:19 AM
KalVista Pharmaceuticals to Present at Stifel Healthcare ConferenceKalVista Pharmaceuticals to Present at Stifel Healthcare Conference
finance.yahoo.com - November 8 at 11:19 AM
KalVista Pharmaceuticals (KALV) vs. Sinovac Biotech (SVA) Head-To-Head ReviewKalVista Pharmaceuticals (KALV) vs. Sinovac Biotech (SVA) Head-To-Head Review
www.americanbankingnews.com - October 30 at 9:22 PM
BRIEF-Longwood Fund II reports 8.7 pct stake in Kalvista Pharmaceuticals ‍BRIEF-Longwood Fund II reports 8.7 pct stake in Kalvista Pharmaceuticals ‍
www.reuters.com - October 21 at 7:09 PM
KalVista Pharmaceuticals Inc (KALV): Time For A Financial Health CheckKalVista Pharmaceuticals Inc (KALV): Time For A Financial Health Check
finance.yahoo.com - October 21 at 7:09 PM
KalVista, Notable Investment and Collaboration AgreementKalVista, Notable Investment and Collaboration Agreement
finance.yahoo.com - October 18 at 5:57 AM
Insider Buying: KalVista Pharmaceuticals, Inc. (KALV) Director Buys 850,000 Shares of StockInsider Buying: KalVista Pharmaceuticals, Inc. (KALV) Director Buys 850,000 Shares of Stock
www.americanbankingnews.com - October 16 at 7:22 PM
KalVista Pharmaceuticals, Inc. (KALV) Given New $27.00 Price Target at BTIG ResearchKalVista Pharmaceuticals, Inc. (KALV) Given New $27.00 Price Target at BTIG Research
www.americanbankingnews.com - October 16 at 10:08 AM
Holdings A/S Novo Sells 2,725,283 Shares of KalVista Pharmaceuticals, Inc. (KALV) StockHoldings A/S Novo Sells 2,725,283 Shares of KalVista Pharmaceuticals, Inc. (KALV) Stock
www.americanbankingnews.com - October 12 at 10:20 PM
Merck Acquires 9.9% Stake In KalVistaMerck Acquires 9.9% Stake In KalVista
www.rttnews.com - October 12 at 3:02 AM
Todays Research Reports on Stocks to Watch: KalVista Pharmaceuticals and Nutanix Inc.Today's Research Reports on Stocks to Watch: KalVista Pharmaceuticals and Nutanix Inc.
finance.yahoo.com - October 11 at 5:00 PM
Company News For Oct 11, 2017Company News For Oct 11, 2017
finance.yahoo.com - October 11 at 5:00 PM
ETFs with exposure to KalVista Pharmaceuticals, Inc. : October 11, 2017ETFs with exposure to KalVista Pharmaceuticals, Inc. : October 11, 2017
finance.yahoo.com - October 11 at 5:00 PM
KalVista Pharmaceuticals (KALV) Reports Collaboration with Merck (MRK) on Continuing Development of KVD001KalVista Pharmaceuticals (KALV) Reports Collaboration with Merck (MRK) on Continuing Development of KVD001
www.streetinsider.com - October 11 at 5:40 AM
KalVista Pharmaceuticals Inc. (KALV) Is Surging On Merck CollaborationKalVista Pharmaceuticals Inc. (KALV) Is Surging On Merck Collaboration
www.nasdaq.com - October 11 at 5:40 AM
BRIEF-Kalvista Pharmaceuticals announces collaboration with MerckBRIEF-Kalvista Pharmaceuticals announces collaboration with Merck
www.reuters.com - October 11 at 5:40 AM
Analyzing KalVista Pharmaceuticals (KALV) and Peregrine Pharmaceuticals (PPHM)Analyzing KalVista Pharmaceuticals (KALV) and Peregrine Pharmaceuticals (PPHM)
www.americanbankingnews.com - October 10 at 10:20 PM
KalVista Pharmaceuticals Announces Collaboration with MerckKalVista Pharmaceuticals Announces Collaboration with Merck
finance.yahoo.com - October 10 at 7:35 PM
UPDATE: KalVista shares surge 111% on news of Merck ownership stake, collaborationUPDATE: KalVista shares surge 111% on news of Merck ownership stake, collaboration
finance.yahoo.com - October 10 at 7:35 PM
KalVista Pharma Wins Big on Merck CollaborationKalVista Pharma Wins Big on Merck Collaboration
finance.yahoo.com - October 10 at 7:35 PM
KalVista Shares Skyrocket On Merck Collaboration, Ovid Pops -- Biotech MoversKalVista Shares Skyrocket On Merck Collaboration, Ovid Pops -- Biotech Movers
finance.yahoo.com - October 10 at 7:35 PM
​Merck takes stake in small Cambridge rare disease biotech, lifting shares​Merck takes stake in small Cambridge rare disease biotech, lifting shares
finance.yahoo.com - October 10 at 7:34 PM
Small-Cap Biotech Rockets After Dow's Merck Buys 10% StakeSmall-Cap Biotech Rockets After Dow's Merck Buys 10% Stake
finance.yahoo.com - October 10 at 7:34 PM
Should You Buy KalVista Pharmaceuticals Inc (KALV) For This Reason?Should You Buy KalVista Pharmaceuticals Inc (KALV) For This Reason?
finance.yahoo.com - October 5 at 5:59 AM
Financial Analysis: Kadmon Holdings (KDMN) versus KalVista Pharmaceuticals (KALV)Financial Analysis: Kadmon Holdings (KDMN) versus KalVista Pharmaceuticals (KALV)
www.americanbankingnews.com - September 28 at 10:20 AM
ETFs with exposure to KalVista Pharmaceuticals, Inc. : September 19, 2017ETFs with exposure to KalVista Pharmaceuticals, Inc. : September 19, 2017
finance.yahoo.com - September 19 at 9:59 PM
KalVista Pharmaceuticals (KALV) and Cardiome Pharma Corporation (CRME) Financial SurveyKalVista Pharmaceuticals (KALV) and Cardiome Pharma Corporation (CRME) Financial Survey
www.americanbankingnews.com - September 18 at 10:30 PM

SEC Filings

KalVista Pharmaceuticals (NASDAQ:KALV) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

KalVista Pharmaceuticals (NASDAQ:KALV) Income Statement, Balance Sheet and Cash Flow Statement

Chart

KalVista Pharmaceuticals (NASDAQ KALV) Stock Chart for Saturday, April, 21, 2018

Loading chart…

This page was last updated on 4/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.